수의용 인슐린 제제 시장(2026-2030년)

The global veterinary insulin drugs market is forecasted to grow by USD 169180.0 thousand during 2025-2030, accelerating at a CAGR of 5.8% during the forecast period. The report on the global veterinary insulin drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of diabetes mellitus in companion animals, technological advancements in insulin delivery and glucose monitoring, rising pet healthcare expenditure and insurance penetration.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global veterinary insulin drugs market is segmented as below:

By Product Type

• Long-acting insulin
• Intermediate-acting insulin
• Combination insulin
• Rapid-acting insulin
• Others

By Distribution Channel

• Offline
• Online

By Raw Material

• Recombinant
• Porcine insulin
• Others

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Russia
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the transition toward species-specific and long-acting insulin analogs as one of the prime reasons driving the global veterinary insulin drugs market growth during the next few years. Also, integration of wearable technology and remote glycemic monitoring and consolidation of veterinary practices and standardized diabetes management protocols will lead to sizable demand in the market.

The report on the global veterinary insulin drugs market covers the following areas:

• Global veterinary insulin drugs market sizing
• Global veterinary insulin drugs market forecast
• Global veterinary insulin drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global veterinary insulin drugs market vendors that include Animalcare Group PLC, bela-pharm GmbH and Co. KG, Bimeda Holdings Ltd., Bioveta AS, Boehringer Ingelheim GmbH, Ceva Sante Animale, CP-Pharma mbH, Dechra Pharmaceuticals Plc, Elanco Animal Health Inc., Kyoritsuseiyaku Corp., Laboratorios Calier S.A., MSD Animal Health, Nippon Zenyaku Kogyo Co.Ltd., Norbrook Laboratories Ltd., Phibro Animal Health Corp., Prodivet pharmaceuticals, Richter Pharma AG, Vetoquinol SA, Virbac SA, Zoetis Inc.. Also, the global veterinary insulin drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Product Type
  • Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Executive Summary - Chart on Market Segmentation by Raw Material
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Veterinary Insulin Drugs Market 2020 - 2024
  • Historic Market Size - Data Table on Global Veterinary Insulin Drugs Market 2020 - 2024 ($ thousand)
• 5.2 Product Type segment analysis 2020 - 2024
  • Historic Market Size - Product Type Segment 2020 - 2024 ($ thousand)
• 5.3 Distribution Channel segment analysis 2020 - 2024
  • Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ thousand)
• 5.4 Raw Material segment analysis 2020 - 2024
  • Historic Market Size - Raw Material Segment 2020 - 2024 ($ thousand)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ thousand)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ thousand)

6 Qualitative Analysis

• 6.1 Impact of AI on Global Veterinary Insulin Drugs Market
• 6.2 Impact of geopolitical conflicts on Global Veterinary Insulin Drugs Market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Product Type

• 8.1 Market segments
• 8.2 Comparison by Product Type
• 8.3 Long-acting insulin - Market size and forecast 2025-2030
• 8.4 Intermediate-acting insulin - Market size and forecast 2025-2030
• 8.5 Combination insulin - Market size and forecast 2025-2030
• 8.6 Rapid-acting insulin - Market size and forecast 2025-2030
• 8.7 Others - Market size and forecast 2025-2030
• 8.8 Market opportunity by Product Type
  • Market opportunity by Product Type ($ thousand)

9 Market Segmentation by Distribution Channel

• 9.1 Market segments
• 9.2 Comparison by Distribution Channel
• 9.3 Offline - Market size and forecast 2025-2030
• 9.4 Online - Market size and forecast 2025-2030
• 9.5 Market opportunity by Distribution Channel
  • Market opportunity by Distribution Channel ($ thousand)

10 Market Segmentation by Raw Material

• 10.1 Market segments
• 10.2 Comparison by Raw Material
• 10.3 Recombinant - Market size and forecast 2025-2030
• 10.4 Porcine insulin - Market size and forecast 2025-2030
• 10.5 Others - Market size and forecast 2025-2030
• 10.6 Market opportunity by Raw Material
  • Market opportunity by Raw Material ($ thousand)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 Germany - Market size and forecast 2025-2030
  • 12.4.2 UK - Market size and forecast 2025-2030
  • 12.4.3 France - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Spain - Market size and forecast 2025-2030
  • 12.4.6 The Netherlands - Market size and forecast 2025-2030
  • 12.4.7 Russia - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 Japan - Market size and forecast 2025-2030
  • 12.5.2 China - Market size and forecast 2025-2030
  • 12.5.3 Indonesia - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 India - Market size and forecast 2025-2030
  • 12.5.6 Thailand - Market size and forecast 2025-2030
  • 12.5.7 Singapore - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Australia - Market size and forecast 2025-2030
  • 12.6.2 UAE - Market size and forecast 2025-2030
  • 12.6.3 Brazil - Market size and forecast 2025-2030
  • 12.6.4 South Africa - Market size and forecast 2025-2030
  • 12.6.5 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.6 Turkey - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ thousand)
  • Data Tables on Market opportunity by geography ($ thousand)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Increasing prevalence of diabetes mellitus in companion animals
  • Technological advancements in insulin delivery and glucose monitoring
  • Rising pet healthcare expenditure and insurance penetration
• 13.2 Market challenges
  • Prohibitive costs of lifelong therapy and economic barriers to treatment
  • Owner compliance and complexity of chronic disease management
  • Supply chain volatility and cold chain logistics requirements
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Transition toward species-specific and long-acting insulin analogs
  • Integration of wearable technology and remote glycemic monitoring
  • Consolidation of veterinary practices and standardized diabetes management protocols

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 Animalcare Group PLC
  • Animalcare Group PLC - Overview
  • Animalcare Group PLC - Business segments
  • Animalcare Group PLC - Key offerings
  • Animalcare Group PLC - Segment focus
  • SWOT
• 15.5 bela-pharm GmbH and Co. KG
  • bela-pharm GmbH and Co. KG - Overview
  • bela-pharm GmbH and Co. KG - Product / Service
  • bela-pharm GmbH and Co. KG - Key offerings
  • SWOT
• 15.6 Bimeda Holdings Ltd.
  • Bimeda Holdings Ltd. - Overview
  • Bimeda Holdings Ltd. - Product / Service
  • Bimeda Holdings Ltd. - Key offerings
  • SWOT
• 15.7 Boehringer Ingelheim GmbH
  • Boehringer Ingelheim GmbH - Overview
  • Boehringer Ingelheim GmbH - Product / Service
  • Boehringer Ingelheim GmbH - Key offerings
  • SWOT
• 15.8 Ceva Sante Animale
  • Ceva Sante Animale - Overview
  • Ceva Sante Animale - Product / Service
  • Ceva Sante Animale - Key offerings
  • SWOT
• 15.9 Dechra Pharmaceuticals Plc
  • Dechra Pharmaceuticals Plc - Overview
  • Dechra Pharmaceuticals Plc - Product / Service
  • Dechra Pharmaceuticals Plc - Key offerings
  • SWOT
• 15.10 Elanco Animal Health Inc.
  • Elanco Animal Health Inc. - Overview
  • Elanco Animal Health Inc. - Product / Service
  • Elanco Animal Health Inc. - Key offerings
  • SWOT
• 15.11 Kyoritsuseiyaku Corp.
  • Kyoritsuseiyaku Corp. - Overview
  • Kyoritsuseiyaku Corp. - Product / Service
  • Kyoritsuseiyaku Corp. - Key offerings
  • SWOT
• 15.12 Laboratorios Calier S.A.
  • Laboratorios Calier S.A. - Overview
  • Laboratorios Calier S.A. - Product / Service
  • Laboratorios Calier S.A. - Key offerings
  • SWOT
• 15.13 Nippon Zenyaku Kogyo Co.Ltd.
  • Nippon Zenyaku Kogyo Co.Ltd. - Overview
  • Nippon Zenyaku Kogyo Co.Ltd. - Product / Service
  • Nippon Zenyaku Kogyo Co.Ltd. - Key offerings
  • SWOT
• 15.14 Norbrook Laboratories Ltd.
  • Norbrook Laboratories Ltd. - Overview
  • Norbrook Laboratories Ltd. - Product / Service
  • Norbrook Laboratories Ltd. - Key offerings
  • SWOT
• 15.15 Phibro Animal Health Corp.
  • Phibro Animal Health Corp. - Overview
  • Phibro Animal Health Corp. - Business segments
  • Phibro Animal Health Corp. - Key offerings
  • Phibro Animal Health Corp. - Segment focus
  • SWOT
• 15.16 Richter Pharma AG
  • Richter Pharma AG - Overview
  • Richter Pharma AG - Product / Service
  • Richter Pharma AG - Key offerings
  • SWOT
• 15.17 Vetoquinol SA
  • Vetoquinol SA - Overview
  • Vetoquinol SA - Business segments
  • Vetoquinol SA - Key offerings
  • Vetoquinol SA - Segment focus
  • SWOT
• 15.18 Zoetis Inc.
  • Zoetis Inc. - Overview
  • Zoetis Inc. - Business segments
  • Zoetis Inc. - Key offerings
  • Zoetis Inc. - Segment focus
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations